The targeted oral, once-daily phosphodiesterase 4 inhibitor roflumilast and the leukotriene receptor antagonist montelukast do not exhibit significant pharmacokinetic interactions.
about
Roflumilast (daliresp): a novel phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary diseaseTreatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor.Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary diseasePharmacokinetic evaluation of roflumilast.Phosphodiesterase-4 inhibitor therapy for lung diseases.
P2860
The targeted oral, once-daily phosphodiesterase 4 inhibitor roflumilast and the leukotriene receptor antagonist montelukast do not exhibit significant pharmacokinetic interactions.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
The targeted oral, once-daily ...... pharmacokinetic interactions.
@en
The targeted oral, once-daily ...... pharmacokinetic interactions.
@nl
type
label
The targeted oral, once-daily ...... pharmacokinetic interactions.
@en
The targeted oral, once-daily ...... pharmacokinetic interactions.
@nl
prefLabel
The targeted oral, once-daily ...... pharmacokinetic interactions.
@en
The targeted oral, once-daily ...... pharmacokinetic interactions.
@nl
P2093
P2860
P356
P1476
The targeted oral, once-daily ...... pharmacokinetic interactions.
@en
P2093
Andreas Hünnemeyer
Christoph H Gleiter
Gabriele M Böhmer
Gezim Lahu
Marcus Wenger
Nassr Nassr
Robert Hermann
Silke Templin
P2860
P304
P356
10.1177/0091270008330980
P577
2009-04-01T00:00:00Z